Struggling Marinus gets a bump out of a positive PhII snapshot
A little more than six months since its stock price was crushed by a failed late-stage program for its leading — and only — drug, tiny biotech microcap Marinus $MRNS saw its shares shoot up this morning after it offered a positive Phase II snapshot on a handful of patients who suffer from a rare genetic ailment.
Investigators flipped the first card of its Phase II hand for ganaxolone in treating CDKL5, which triggers severe seizures and neurological damage among the children afflicted by it. One of four patients had to drop out from a lack of response, but investigators say that the three others experienced a reduction in seizures ranging from 52% to 88%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.